美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Avalyn Pharma

31.52

-1.9100-5.71%

盤後：31.520.00000.00%19:30 EDT

成交量：66.48萬

成交額：2,102.63萬

市值：13.97億

市盈率：-13.53

高：34.04

開：33.15

低：31.18

收：33.43

52周最高：40.17

52周最低：24.15

股本：4,433.31萬

流通股本：1,666.67萬

量比：2.35

換手率：3.99%

股息：- -

股息率：- -

每股收益(TTM):-2.3300

每股收益(LYR):-87.7434

淨資產收益率：-68.34%

總資產收益率：-41.74%

市淨率：3.51

市盈率(LYR):-0.36

資料載入中...

總覽公司新聞資訊公告

新聞稿：Avalyn任命Robert J. Meyer醫學博士為董事會成員

Avalyn完成AP01（吸入性吡非尼酮）針對進展性肺纖維化患者的2b期Mist試驗目標入組

Avalyn Pharma 將公布AP01（吸入性吡非尼酮）治療肺纖維化的更多長期數據

異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%

肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克

Avalyn Pharma任命行業領袖Adam Golden與Frank Salisbury，強化領導團隊以支持長期增長

肺纖維化生物技術公司Avalyn Pharma(AVLN.US)IPO定價16至18美元擬募資2.01億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/AVLN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"AVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":31.52,"timestamp":1789761600000,"preClose":33.43,"halted":0,"volume":664783,"hourTrading":{"tag":"盘后","latestPrice":31.52,"preClose":31.52,"latestTime":"19:30 EDT","volume":111872,"amount":3526211.3479,"timestamp":1789774205644,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.057134310499551304,"floatShares":16666700,"shares":44333095,"eps":-2.33,"marketStatus":"休市中","change":-1.91,"latestTime":"09-18 16:00:00 EDT","open":33.15,"high":34.04,"low":31.175,"amount":21026289.215183,"amplitude":0.085701,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.33,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":33.43,"preHourTrading":{"tag":"盘前","latestPrice":32,"preClose":33.43,"latestTime":"07:23 EDT","volume":202,"amount":6750.4998319999995,"timestamp":1789730623703,"change":-1.43,"changeRate":-0.042776,"amplitude":0.042776},"postHourTrading":{"tag":"盘后","latestPrice":31.52,"preClose":31.52,"latestTime":"19:30 EDT","volume":111872,"amount":3526211.3479,"timestamp":1789774205644,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.3479514239019585,"impliedVol":0.6311,"impliedVolPercentile":0.45},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVLN\",,,,,undefined,":{"symbol":"AVLN","floatShares":16666700,"roa":"-41.74%","roe":"-68.34%","lyrEps":-87.743381,"volumeRatio":2.3479514239019585,"shares":44333095,"dividePrice":0,"high":34.04,"amplitude":0.085701,"preClose":33.43,"low":31.175,"week52Low":24.15,"pbRate":"3.51","week52High":40.17,"institutionHeld":0,"latestPrice":31.52,"eps":-2.33,"divideRate":0,"volume":664783,"delay":0,"ttmEps":-2.33,"open":33.15,"prevYearClose":18,"prevWeekClose":33.57,"prevMonthClose":34.73,"prevQuarterClose":32.92,"fiveDayClose":33.57,"twentyDayClose":37.13,"sixtyDayClose":30.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"AVLN","fiscalQuarterEnding":"2026/06","expectedEps":-1.03,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"pre","actualEps":-0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AVLN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1781755200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AVLN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AVLN","date":"2026-09-18","current":-13.527897,"percent":0.489583,"low":-16.842577,"twenty":-15.433221,"median":-14.265483,"eighty":-13.287874,"high":-8.833116,"avg":-14.368988,"sd":1.265845,"marketCap":1482055365},"quantilePoints":[{"date":"2026-05-01","current":-14.471589,"twenty":-13.343894,"median":-11.652352,"eighty":-9.960811,"marketCap":1233037266},{"date":"2026-05-08","current":-13.215324,"twenty":-14.430368,"median":-13.598092,"eighty":-13.264397,"marketCap":1125998425},{"date":"2026-05-15","current":-15.026112,"twenty":-14.666899,"median":-14.368536,"eighty":-13.42143,"marketCap":1280284879},{"date":"2026-05-22","current":-13.941602,"twenty":-14.643344,"median":-13.941602,"eighty":-13.42143,"marketCap":1187880255},{"date":"2026-05-29","current":-13.931787,"twenty":-14.643344,"median":-13.931787,"eighty":-13.215324,"marketCap":1187044014},{"date":"2026-06-05","current":-13.244767,"twenty":-14.510847,"median":-13.774754,"eighty":-13.102456,"marketCap":1128507148},{"date":"2026-06-12","current":-13.774754,"twenty":-14.471589,"median":-13.774754,"eighty":-13.161343,"marketCap":1173664159},{"date":"2026-06-18","current":-14.383258,"twenty":-14.479441,"median":-13.794383,"eighty":-13.204528,"marketCap":1225511097},{"date":"2026-06-26","current":-13.585419,"twenty":-14.649233,"median":-13.936694,"eighty":-13.238878,"marketCap":1284773093},{"date":"2026-07-02","current":-14.143275,"twenty":-14.655122,"median":-14.03484,"eighty":-13.265378,"marketCap":1337529476},{"date":"2026-07-10","current":-13.557292,"twenty":-14.643344,"median":-13.937009,"eighty":-13.265378,"marketCap":1282113107},{"date":"2026-07-17","current":-12.038425,"twenty":-14.576758,"median":-13.784568,"eighty":-13.15846,"marketCap":1138473879},{"date":"2026-07-24","current":-13.937009,"twenty":-14.519455,"median":-13.774754,"eighty":-13.193732,"marketCap":1318022914},{"date":"2026-07-31","current":-13.740119,"twenty":-14.495144,"median":-13.755125,"eighty":-13.157019,"marketCap":1299403014},{"date":"2026-08-07","current":-15.329303,"twenty":-14.523759,"median":-13.762486,"eighty":-13.165961,"marketCap":1449692206},{"date":"2026-08-14","current":-15.696852,"twenty":-14.725787,"median":-13.774754,"eighty":-13.189862,"marketCap":1621704615},{"date":"2026-08-21","current":-15.932863,"twenty":-15.087944,"median":-13.934398,"eighty":-13.227101,"marketCap":1646087817},{"date":"2026-08-28","current":-15.666815,"twenty":-15.573456,"median":-13.941602,"eighty":-13.249768,"marketCap":1618601298},{"date":"2026-09-04","current":-15.207667,"twenty":-15.433025,"median":-14.088821,"eighty":-13.261019,"marketCap":1571164886},{"date":"2026-09-11","current":-14.877252,"twenty":-15.620135,"median":-14.133223,"eighty":-13.26914,"marketCap":1537028403},{"date":"2026-09-18","current":-14.345155,"twenty":-15.433221,"median":-14.265483,"eighty":-13.287874,"marketCap":1482055365}],"updateTime":1789870001397},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVLN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1123407353","title":"新聞稿：Avalyn任命Robert J. Meyer醫學博士為董事會成員","url":"https://stock-news.laohu8.com/highlight/detail?id=1123407353","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123407353?lang=zh_tw&edition=fundamental","pubTime":"2026-09-17 04:02","pubTimestamp":1789588975,"startTime":"0","endTime":"0","summary":"波士顿，2026年9月16日——Avalyn Pharma Inc.是一家处于临床阶段的生物制药公司，致力于开创吸入式疗法，以变革严重罕见呼吸系统疾病的治疗模式。该公司今日宣布，任命杰出肺病专家、美国食品药品监督管理局前高级领导者RobertJ. Meyer医学博士为其董事会成员。Meyer博士最近曾担任Greenleaf Health药品与生物制品部门负责人。Meyer博士拥有超过25年的领导经验，涵盖监管、学术和行业领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4585","BK4007","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150445147","title":"Avalyn完成AP01（吸入性吡非尼酮）針對進展性肺纖維化患者的2b期Mist試驗目標入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1150445147","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150445147?lang=zh_tw&edition=fundamental","pubTime":"2026-06-17 20:01","pubTimestamp":1781697684,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，其针对进展性肺纤维化患者研发的药物AP01（吸入性吡非尼酮）的2b期Mist临床试验，现已完成目标患者入组工作。这一关键里程碑标志着该试验已进入新的数据收集与分析阶段，为评估该吸入式疗法的有效性与安全性奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199282092","title":"Avalyn Pharma 將公布AP01（吸入性吡非尼酮）治療肺纖維化的更多長期數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1199282092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199282092?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 20:01","pubTimestamp":1779364877,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，关于其吸入性吡非尼酮（AP01）用于治疗肺纤维化的更多长期研究数据，将于2026年欧洲风湿病联盟大会上公布。这些数据有望进一步验证该疗法的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197256686","title":"異動解讀 | Avalyn Pharma IPO首日盤中大漲44.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256686","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197256686?lang=zh_tw&edition=fundamental","pubTime":"2026-05-01 01:26","pubTimestamp":1777570002,"startTime":"0","endTime":"0","summary":"Avalyn Pharma今日盘中大涨44.44%，引起了市场的广泛关注。消息面上，Avalyn Pharma是一家专注于开发治疗罕见呼吸系统疾病吸入式药物的生物技术公司，其于今日正式在纳斯达克全球精选市场挂牌交易。这两款药物分别为吡非尼酮和尼达尼布的吸入制剂，针对特发性肺纤维化等疾病，旨在提升疗效并减少副作用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507639","title":"肺纖維化生物技術公司Avalyn Pharma IPO定價18美元募資3億，今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631507639?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 15:07","pubTimestamp":1777532834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家处于二期临床试验阶段的生物技术公司，专注于开发治疗罕见呼吸系统疾病的吸入式药物。Avalyn的股票预计于4月30日(周四)正式在纳斯达克全球精选市场挂牌交易。作为临床阶段的生物技术企业，Avalyn Pharma致力于研发针对罕见呼吸系统疾病的吸入式抗纤维化疗法。其核心候选药物AP01和AP02分别为吡非尼酮和尼达尼布的吸入制剂，旨在将已获批的抗纤维化药物直接递送至肺部，提升局部药物暴露量并减少全身性副作用。","market":"us","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437125.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SQQQ","QLD","PSQ","QQQJ","MNQmain","QQQM","BK1147","TQQY","QYLG","QQQY","TQQQ","BK4007","QQQ","GPIQ","QID","QQQA","NVIW.SI","QDTE","IYW","FTEC","ONEQ","AVLN","QQQE","JEPQ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154944245","title":"Avalyn Pharma任命行業領袖Adam Golden與Frank Salisbury，強化領導團隊以支持長期增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1154944245","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154944245?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 20:28","pubTimestamp":1777292892,"startTime":"0","endTime":"0","summary":"生物制药公司Avalyn Pharma宣布两项关键高层任命，旨在加强其领导团队实力，为公司长期发展提供战略支持。公司正式任命Adam Golden和Frank Salisbury担任重要领导职务，两位行业资深人士的加入将助力Avalyn推进其创新疗法研发管线。此次人事变动彰显了Avalyn Pharma在呼吸疾病治疗领域持续扩张的决心。通过对领导团队的战略性补强，Avalyn进一步巩固了其在新药研发领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629818634","title":"肺纖維化生物技術公司Avalyn Pharma(AVLN.US)IPO定價16至18美元 擬募資2.01億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629818634","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629818634?lang=zh_tw&edition=fundamental","pubTime":"2026-04-24 15:07","pubTimestamp":1777014466,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家专注于开发用于治疗罕见呼吸系统疾病的吸入式药物的二期生物技术公司，于周四公布了其首次公开募股条款。作为一家临床阶段的生物技术公司，Avalyn Pharma致力于开发用于治疗罕见呼吸系统疾病的吸入式抗纤维化疗法。自 2011 年成立以来，Avalyn 已累计获得超过 3.8 亿美元的私募股权投资。Avalyn Pharma成立于2011年，计划在纳斯达克上市，股票代码为AVLN。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","UUP","AVLN","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}